top of page

PRESS RELEASE

2023.11.18

Logga C4C.png

Cell4Cure appoints Sharon Longhurst as its CMC expert

Solna, Sweden, 18 November 2023, Cell4Cure AB - A Swedish private ATMP company working with antigen-specific dendritic cell mediated tolerance, aiming for curing disease where the immune system has become the enemy - today announced that they have appointed Sharon Longhurst, Advanced Biologics Consulting, as its Chemistry, Manufacturing and Controls (CMC) expert.

Sharon Longhurst has a long history within the field of ATMP having among other things worked for regulatory authorities as well as in biotechs, e.g. Mendus AB, Idogen AB. She now runs an independent consulting business in Advanced Biologics Consulting.

Christina Herder, co-founder and board member: “Sharon has the important CMC competence from both a regulatory body and an SME perspective. She knows our technology platform and we look forward to working together again.”

Sharon Longhurst: “I am happy to continue the support of the proprietary manufacturing process that now lives on in C4C. This process effectively generates autologous tolerogenic dendritic cells in an antigen specific manner, which has the potential to provide an alternative therapeutic approach for the treatment of e.g. autoimmune diseases. An important challenge from a CMC perspective is the ability to supply products of exceptional quality in a cost-effective way. C4C believes the ability to manufacture the product using automated closed production platforms and where possible using automated technologies for release testing is the future. This will pave the way for potentially developing point of care supply strategies for later phase clinical development."

 

For more information, please contact;

Christina Herder, CEO

Telephone: +46 703747156

E-mail: christina.herder@cell4cure.com

 

About Cell4Cure

Cell4Cure AB is a Swedish, privately held cell therapy company committed to the development of treatments for inducing of immune tolerance. The company’s proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance for the prevention or cure of diseases where the immune system is the enemy.

The company’s first clinical study, Toler8, is focusing on inducing tolerance to FVIII thereby preventing the occurrence of FVIII inhibitors, i.e. neutralizing antibodies, in hemophilia A patients.

Cell4Cure will as a first step deliver value to patients and shareholders by advancing this program to clinical proof of concept.

For more information visit www.cell4cure.com.

bottom of page